In connection with the recruitment of a new CFO, Peptonic will restructure and strengthen its finance department to fully manage the company's finances internally. The initiative reflects Peptonic's ambition to evolve into a global company, where a robust financial infrastructure with broad expertise is crucial for creating tailored solutions for various parts of the company's operations as well as meeting statutory requirements in different countries. By strengthening the finance department, Peptonic will also be able to work more efficiently and better support the operational activities for future growth.
A recruitment process to fill positions within the finance department has been initiated.
For more information, please contact:
Email: anna.linton@peptonicmedical.se
Phone: +46 70-940 85 00
About Peptonic
Peptonic Medical continuously aims to broaden its product portfolio through acquisitions and the development of innovative and competitive products in-house. The company's mousse-based drug delivery technology, Venerol, and the gel base in VagiVital create favorable conditions for expanding the portfolio. Central to the growth strategy is the geographic expansion of VagiVital and Vernivia through local partners.
The company is headquartered in Stockholm, Sweden, with a branch in New York, NY, and an R&D unit in Caesarea, Israel.
Peptonic Medical was founded in 2009, and the company's shares have been listed on the
https://news.cision.com/peptonic-medical-ab/r/peptonic-medical-ab-announces-that-cfo-is-leaving-for-new-challenges-and-that-the-company-s-financia,c3954415
(c) 2024 Cision. All rights reserved., source